Recombinant Immune Modulators

recombinant immune modulators   Published September 2016  •  Catalog no. RJM456D  •  Price US $3,850

In spite of the growing understanding of the underlying mechanisms for a host of diseases and disease families, a number of conditions continue to challenge clinicians and their patients. Because of the individual genetic variability underlying the incidence and severity of symptoms, regional variations in the global market for immune modulation therapeutics can be significant. This variability is compounded by differences in treatment protocols and cultural factors, which combine to make alliance partnerships with regional players of increasing importance. Over the past two years the introduction of new and improved immune modulators for treating refractory diseases has created new options for clinicians and patients. This view is being reinforced by pipeline candidates that will further the effort to improve treatment protocols for patients.

Bar_Graph   Recombinant Immune Modulators Report Brochure (Download PDF)

Blue document    Recombinant Immune Modulators Report Order Form (Download PDF)

What You Will Learn

• What recombinant immune modulators are currently marketed or in development, who are the suppliers, and what are the product specifics?
• What are the markets being targeted by recombinant immune modulators?
• What are the major factors that will drive recombinant immune modulators product demand?
• What is the addressable market for immune modulators?
• What are the key sourcing/supply chain factors influencing the recombinant immune modulator market ?
• Who are the significant players in this segment? What are their strategies? Who are their alliance partners?

Recombinant Immune Modulators – Summary of Contents


Executive Summary

The Market Opportunity

Prevalence and Incidence of Hemophilia
Treatment Factors
Disease Type and Severity
Administration & Packaging
Reimbursement & Managed Care
Demand Drivers
Competitive Landscape

Approved Recombinant Immune Modulators

Fusion Proteins
Monoclonal Antibodies

Product Technology Factors

Therapeutic Targets
Receptors, Inhibitors and Blockers
PEGylated Formulations

Disease Segment Analysis and Market Data

Autoimmune Diseases
Arthritis & Related Conditions
Multiple Sclerosis
Crohn’s Disease
Infectious Disease
Inherited Inflammatory Disorders
Primary Immunodeficiency Disease
Transplant Organ Rejection
Ulcerative Colitis

Market Factors

Regulatory Issues
Patient Compliance and Ease of Use
Healthcare Economics

Company Profiles